This course is part of the Safe and Effective Pain Care: A Comprehensive Guide for Opioid Prescribing in Primary Care curriculum.
Female doctor talking to a patient

This course is part of the Safe and Effective Pain Care: A Comprehensive Guide for Opioid Prescribing in Primary Care curriculum.

Interactive Learning

1.25 CME Credit

Part 1: Pain and Opioid Use Disorder: Assessment, Risk, and Management
This course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

Pain and Opioid Use Disorder: Assessment, Risk, and Management is Part 1 of the 4-part curriculum, Safe and Effective Pain Care: A Comprehensive Guide for Opioid Prescribing in Primary Care, which examines the full spectrum of pain management options available to clinicians, including the safe and effective use of opioids. 
 
Part 1 of this curriculum establishes the essential knowledge and clinical skills needed for safe, effective pain management and responsible opioid prescribing. You’ll learn how to recognize and treat opioid use disorder, assess pain more accurately, and identify risk for misuse before it happens. You’ll also explore practical steps for safer prescribing, including informed consent and pain agreements. Walk away with strategies you can use in clinic tomorrow.
 
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see  https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).
 
Each activity will cover various state-specific content and guidelines, also available for download.
 
Learners must complete four parts, Part 1: Pain and Opioid Use Disorder: Assessment, Risk, and Management , Part 2: Treating Pain Safely: First-Line Strategies and Opioid Fundamentals, Part 3: Opioid Prescribing in Practice: Initiation, Titration, Monitoring, and Safety, and Part 4: OUD in Practice: From Brief Intervention to Treatment with an AI Standardized Patient in order to be a fully FDA Blueprint compliant completer.

Begin

CME Information

1.25 AMA PRA Category 1 Credits™, 1.25 ABIM MOC or 1.25 AANP, including 0.63 AANP Pharm

Release Date: 12/1/2025

Expiration Date: 10/31/2026

Topics

Faculty

Learning Objectives

  • Assess pain effectively while identifying risk factors for nonmedical use of opioids, substance/opioid use disorders
  • Diagnose and manage opioid use disorder, using evidence-based approaches, including referrals to specialists when needed
  • Define key concepts, mechanisms, and classifications of pain to enhance clinical understanding
  • Counsel patients on the safe use, storage, and disposal of opioid analgesics, including overdose reversal agents

State Licensure Requirements

This activity satisfies topic-specific CME/CE requirements (pain management, controlled substances, etc.) of many state licensing boards. Please check with your state’s licensing boards for specific requirements, and print this page as appropriate for documentation. For more information, visit https://www.pri-med.com/state/state-mandated 

Iowa: This activity is designed to satisfy requirements of ARNPs, for CE regarding the US Centers for Disease Control and Prevention Guideline for prescribing opioids for chronic pain. Please print this page as documentation, for submission with your CE certificate.

Kentucky: This activity is approved for HB1/Prescribing Controlled Substances and 201 KAR 9:270 Addiction Medicine (MD/PA) by the Kentucky Board of Medical Licensure, ID# 1125-H4.0-PMI2025B

Louisiana: This activity is approved for Controlled Substances by the Louisiana State Board of Nursing

Texas: This activity is approved for Pain Management and Prescription of Opioids requirements from the Texas Medical Board/Board of Nursing, as well as Medical Ethics and/or Professional Responsibility.

This activity satisfies training requirements for the MATE Act, which requires all DEA-registered practitioners to complete 8 hours of CME/CE credit on opioid or other substance use disorders.

Faculty

Charles E. Argoff, MD, FABPM

Vice Chair, Albany Medical College, Professor of Neurology and Urology

Director, Comprehensive Pain Center, Albany Medical Center, Director, Pain Management Fellowship, Albany, New York

Learn More

Disclosures

The following relevant financial relationships have been disclosed by those in a position to influence the content of this activity. All have been mitigated by Pri-Med Institute:

Charles Argoff, MD, FABPM: Speaker for Averitas Pharma, AbbVie, Lilly, Lundbeck, Impel Pharmaceuticals, Kowa Pharmaceuticals, Nevro Corporation, Scilex Pharmaceuticals, Teva Pharmaceuticals; Researcher for AbbVie; Consultant for Collegium Pharmaceutical, Nevro Corporation, Pain Scripts, Scilex Pharmaceuticals, Shiratronics, Tris Pharma, Vertex Pharmaceuticals, Vertamical, and Xgene Pharma; Investigator for Lundbeck, and Teva Pharmaceuticals; Stock Holder for Pfizer and Trevena.

All others in control of content for this activity have disclosed no relevant financial relationships.

CME Information

AMA PRA Category 1 Credits™

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

Accreditation Statement

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider Number 040308. 

 

Designation Statement

This activity is approved for 1.25 contact hour, which includes 0.63 hour of pharmacology. 

MOC Credit Information

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points and Patient Safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Pri-Med Institute reports completion information to ACCME on a monthly basis, in the first week of each month. Pri-Med Institute reports completion information to ACCME on a monthly basis, in the first week of each month.


Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). For guidance on how clinicians can attest to participation in a MIPS Improvement Activity, visit https://qpp.cms.gov/mips/improvement-activities" 

mips logo

Instructions for Obtaining Credit

Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 4 out of the 5 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen. For PAs, the NCCPA accepts for Category 1 CME credit activities designated for AMA PRA Category 1 Credit.

Commercial Supporter

This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies

Education Partner

Miller Medical Communications, LLC

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.

Part 1: Pain and Opioid Use Disorder: Assessment, Risk, and Management

Begin